GH use in the transition of adolescence to adulthood

Endocrine Development

Volumn 18, Issue , 2010, Pages 109-125

  Mauras, Nelly ^a  

^a NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; PLACEBO; SOMATOMEDIN C;

ADOLESCENCE; ADULTHOOD; BODY COMPOSITION; BODY FAT; BODY HEIGHT; BONE DENSITY; BONE MASS; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FOLLOW UP; GROWTH HORMONE DEFICIENCY; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; INSULIN TOLERANCE TEST; LIPID METABOLISM; LOW DRUG DOSE; MULTIPLE PITUITARY HORMONE DEFICIENCY; MUSCLE STRENGTH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROVOCATION TEST; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW;

ADOLESCENT; ADOLESCENT DEVELOPMENT; ENDOCRINE SYSTEM DISEASES; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; PUBERTY; YOUNG ADULT;

EID: 84875403471     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000316131     Document Type: Review

References (59)

1. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML; Endocrine Society's Clinical Guidelines Subcommittee, Stephens PA: Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006;91:1621-1634.
2. Vance ML, Mauras N: Growth hormone therapy in adults and children. N Engl J Med 1999;341: 1206-1216.
3. Nørelund H, Vahl N, Juul A, Müller N, Alberti KG, Skakkebaek NE, Christiansen JS, Jøgensen JO: Continuation of growth hormone (GH) therapy in GH-deficient patients during transition from childhood to adulthood: impact on insulin sensitivity and substrate metabolism. J Clin Endocrinol Metab 2000;85:1912-1917.
4. Drake WM, Carroll PV, Maher KT, Metcalfe KA, Camacho-Hübner C, Shaw NJ, Dunger DB, Cheetham TD, Savage MO, Monson JP: The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. J Clin Endocrinol Metab 2003;88:1658-1663. (Pubitemid 36623384)
5. Shalet SM, Shavrikova E, Cromer M, Child CJ, Keller E, Zapletalova J, Moshang T, Blum WF, Chipman JJ, Quigley CA, Attanasio AF: Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: a 2-year randomized, controlled, dose-ranging study. J Clin Endocrinol Metab 2003;88:4124-4129.
6. Mauras N, Pescovitz OH, Allada V, Messig M, Wajnrajch MP, Lippe B, Transition Study Group: Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double- blind, randomized two-year trial. J Clin Endocrinol Metab 2005;90:3946-3955.
7. Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ; HyposCCS Advisory Board; US HypoCCS Study Group: Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 2002;87:477-485.
8. Maghnie M, Strigazzi C, Tinelli C, Autelli M, Cisternino M, Loche S, Severi F: Growth hormone (GH) deficiency (GHD) of childhood onset: reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults. J Clin Endocrinol Metab 1999;84:1324-1328.
9. Gleeson HK, Gattamaneni HR, Smethurst L, Brennan BM, Shalet SM: Reassessment of growth hormone status is required at final height in children treated with growth hormone replacement after radiation therapy. J Clin Endocrinol Metab 2004; 89:662-666.
10. Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M, European Society of Paediatric Endocrinology: Consensus statement on the management of the GH-treated adolescent in transition to adult care. Eur J Endocrinol 2005; 152:165-170.
11. Radovick S, DiVall S: Approach to the growth hormone-deficient child during transition to adulthood. J Clin Endocrinol Metab 2007;92: 1195-1200.
12. Ho KK; GH Deficiency Consensus Workshop Participants 2007 Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: A statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007;157:695-700.
13. Zucchini S, Pirazzoli P, Baronio F, Gennari M, Bal MO, Balsamo A, Gualandi S, Cicognani A: Effect on adult height of pubertal growth hormone retesting and withdrawal of therapy in patients with previously diagnosed growth hormone deficiency. J Clin Endocrinol Metab 2006;91:4271-4276.
14. Martha PM, Rogol AD, Veldhuis JD, Kerrigan JR, Goodman DW, Blizzard RM: Alterations in the pulsatile properties of circulating growth hormone concentrations during puberty in boys. J Clin Endocrinol Metab 1989;69:563-570.
15. Veldhuis JD, Roemmich JN, Richmond EJ, Rogol AD, Lovejoy JC, Sheffield-Moore M, Mauras N, Bowers CY: Endocrine control of body composition in infancy, childhood, and puberty. Endocr Rev 2005;26:114-146.
16. Ho KK, Hoffman DM: Defining growth hormone deficiency in adults. Metabolism 1995;44(suppl 4):91-96.
17. Maghnie M, Aimaretti G, Bellone S, Bona G, Bellone J, Baldelli R, de Sanctis C, Gargantini L, Gastaldi R, Ghizzoni L, Secco A, Tinelli C, Ghigo E: Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement. Eur J Endocrinol 2005;152:589-596.
18. Biller BM, Samuels MH, Zagar A, Cook DM, Arafah BM, Bonert V, Stavrou S, Kleinberg DL, Chipman JJ, Hartman ML: Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002;87:2067-2079.
19. Darzy KH, Aimaretti G, Wieringa G, Gattamaneni HR, Ghigo E, Shalet SM: The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J Clin Endocrinol Metab 2003;88:95-102.
20. Vahl N, Juul A, Jøgensen JO, ørskov H, Skakkebaek NE, Christiansen JS: Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study. J Clin Endocrinol Metab 2000;85:1874-1881. (Pubitemid 32269292)
21. Attanasio AF, Howell S, Bates PC, Frewer P, Chipman J, Blum WF, Shalet SM: Body composition, IGF-1 and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients. J Clin Endocrinol Metab 2002;87:3368-3372.
22. Underwood LE, Attie KM, Baptista J, Genentech Collaborative Study Group: Growth hormone (GH) dose-response in young adults with childhood onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab 2003;88:5273-5280.
23. Carroll PV, Drake WM, Maher KT, Metcalfe K, Shaw NJ, Dunger DB, Cheetham TD, Camacho- Hübner C, Savage MO, Monson JP: Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth. J Clin Endocrinol Metab 2004;89:3890-3895.
24. Attanasio AF, Shavrikova E, Blum WF, Cromer M, Child CJ, Paskova M, Lebl J, Chipman JJ, Shalet SM, Hypopituitary Developmental Outcome Study Group: Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. J Clin Endocrinol Metab 2004;89:4857-4862.
25. Bengtsson BÅ, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Stahl E, Westberg B, Wilton P, Wuster D: The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. J Clin Endocrinol Metab 1999;84:3929-3935.
26. Christiansen JS, Jorgensen JO: Beneficial effects of GH replacement therapy in adults. Acta Endocrinol 1991;125:7-13.
27. Mauras N, O'Brien KO, Welch S, Rini A, Helgeson K, Vieira NE, Yergey AL: Insulin-like growth factor 1 and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J Clin Endocrinol Metab 2000;85:1686-1694.
28. Cowan FJ, Evans WD, Gregory JW: Metabolic effects of discontinuing growth hormone treatment. Arch Dis Child 1999;80:517-523.
29. Johannsson G, Albertsson-Wikland K, Bengtsson BÅ: Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children. J Clin Endocrinol Metab 1999;84:4516-4524.
30. Kaufmann JM, Taelman P, Vermeulen A, Vandeweghe M: Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab 1992;74:118-123.
31. Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM: Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994;78:669-674.
32. Degerblad M, Bengstsson BA, Bramnert M, Johnell O, Manhem P, Rosen T, Thoren M: Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12 months of GH substitution therapy. Eur J Endocrinol 1995;133:180-188.
33. Janssen YJ, Hamdy NA, Frolich M, Roelfsema F: Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adultonset GH deficiency. J Clin Endocrinol Metab 1998;83:2143-2148.
34. Biller BM, Sesmilo G, Baum HB, Hayden D, Schoenfeld D, Klibanski A: Withdrawal of longterm physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab 2000;85:970-976.
35. Colao A, Di Somma C, Salerno M, Spinelli L, Orio F, Lombardi G: The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab 2002;87:3650-3655.
36. Yarasheski KE, Zachwieja JJ, Campbell JA, Bier DM: Effect of growth hormone and resistance exercise on muscle growth and strength in older men. Am J Physiol 1995;268:E268-E276.
37. Hartman ML, Weltman A, Zagar A, Qualy RL, Hoffman AR, Merriam GR: Growth hormone replacement therapy in adults with growth hormone deficiency improves maximal oxygen consumption independently of dosing regimen or physical activity. J Clin Endocrinol Metab 2008;93:125-130.
38. Gotherstrom G, Bengtsson BA, Sunnerhagen KS, Johsnnsson G, Svensson J: The effects of five-year growth hormone replacement therapy on muscle strength in elderly hypopituitary patients. Clin Endocrinol 2005;62:105-113.
39. Hull KL, Harvey S: Growth hormone therapy and quality of life: possibilities, pitfalls and mechanisms. J Endocrinol 2003;179:311-313.
40. Wirén L, Johannsson G, Bengtsson BA: A prospective investigation of quality of life and psychological well-being after the discontinuation of GH treatment in adolescent patients who had GH deficiency during childhood. J Clin Endocrinol Metab 2001;86:3494-3498.
41. Björk S, Jönsson B, Westphal O, Levin JE: Quality of life of adults with growth hormone deficiency: a controlled study. Acta Paediatr Scand Suppl 1989;356:55-59.
42. Rosén T, Wirén L, Wilhelmsen L, Wiklund I, Bengtsson BÅ: Decreased psychological wellbeing in adult patients with growth hormone deficiency. Clin Endocrinol 1994;40:111-116.
43. Badia X, Lucas A, Sanmarti A, Roset M, Ulied A: One-year follow-up of quality of life in adults with untreated growth hormone deficiency. Clin Endocrinol 1998;49:765-771.
44. Abs R, Bengtsson BÅ, Hernberg-Stahl E, Monson JP, Tauber JP, Wilton P, Wuster C: GH replacement in 1,034 growth hormone-deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol 1999;50:703-713.
45. Sanmarti A, Lucas A, Hawkins F, Webb SM, Ulied A: Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA Study). Socio-economic impact and health status. Collaborative ODA (Observational GH Deficiency in Adults) Group. Eur J Endocrinol 1999;141:481-489.
46. McGauley GA: Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand Suppl 1989;356:70-72.
47. Bengtsson BÅ, Edén S, Lönn L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tolli J, Sjostrom L, Isaksson OG: Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993;76:309-317.
48. Mårdh G, Lundin K, Borg G, Jonsson B, Lindberg A: Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined data from 12 European placebo-controlled clinical trials. Endocrinol Metab 1994;1(suppl A):43-49.
49. Burman P, Broman JE, Hetta J, Wiklund I, Erfurth EM, Hagg E, Karlsson FA: Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab 1995;80:3585-3590.
50. Attanasio AF, Lamberts SW, Matranga AM, Birkett MA, Bates PC, Valk NK, Hilsted J, Bengtsson BA, Strasburger CJ: Adult growth hormone (GH)- deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab 1997;82:82-88.
51. Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S, Strauss B, Stockigt J, Topliss D, Alford F, Hew L, Bode H, Conway A, Handelsman D, Dunn S, Boyages S, Cheung NW, Hurley D: The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults. J Clin Endocrinol Metab 1998;83:107-116.
52. Wirén L, Bengtsson BÅ, Johannsson G: Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency. Clin Endocrinol 1998;48:613-620.
53. Murray RD, Skillicorn CJ, Howell SJ, Lissett CA, Rahim A, Smethurst LE, Shalet SM: Influences on quality of life in GH deficient adults and their effect on response to treatment. Clin Endocrinol 1999;51:565-573.
54. Wallymahmed ME, Foy P, Shaw D, Hutcheon R, Edwards RH, MacFarlane IA: Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3 years. Clin Endocrinol 1997;47:439-446.
55. Baum HB, Katznelson L, Sherman JC, Biller BM, Hayden DL, Schoenfeld DA, Cannistraro KE, Klibanski A: Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1998;83:3184-3189.
56. Florkowski CM, Stevens I, Joyce P, Espiner EA, Donald RA: Growth hormone replacement does not improve psychological well-being in adult hypopituitarism: a randomized crossover trial. Psychoneuroendocrinology 1998;23:57-63.
57. Sandberg DE, MacGillivray MH, Clopper RR, Fung C, LeRoux L, Alliger DE: Quality of life among formerly treated childhood-onset growth hormone-deficient adults: a comparison with unaffected siblings. J Clin Endocrinol Metab 1998;83:1134-1142.
58. Stabler B: Impact of growth hormone (GH) therapy on quality of life along the lifespan of GHtreated patients. Horm Res 2001;56(suppl 1): 55-58.
59. Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J: High-dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech Inc Cooperative Study Group. J Clin Endocrinol Metab 2000; 85:3653-3660.